Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Medtronic
Moodys
Harvard Business School
Dow

Last Updated: June 26, 2022

CLINICAL TRIALS PROFILE FOR PALIPERIDONE PALMITATE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Paliperidone Palmitate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00073320 ↗ Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 2003-08-01 The purpose of the study is to compare the pharmacokinetic parameters (blood concentrations) of i.m. paliperidone palmitate after administration in 2 different injection sites (deltoid or gluteal).
NCT00074477 ↗ Safety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 2 2003-10-01 The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate injection compared to placebo in the treatment of the symptoms of schizophrenia in adults. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings.
NCT00101634 ↗ Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 2004-12-01 The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate compared to placebo in the treatment of the symptoms of schizophrenia in adults. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings.
NCT00111189 ↗ A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia. Completed Janssen-Cilag International NV Phase 3 2005-02-01 The purpose of this study is to evaluate the efficacy of paliperidone palmitate compared with placebo in the prevention of recurrence of the symptoms of schizophrenia and to assess the safety and tolerability of paliperidone palmitate in patients with stable and symptomatic schizophrenia. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings.
NCT00111189 ↗ A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia. Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 2005-02-01 The purpose of this study is to evaluate the efficacy of paliperidone palmitate compared with placebo in the prevention of recurrence of the symptoms of schizophrenia and to assess the safety and tolerability of paliperidone palmitate in patients with stable and symptomatic schizophrenia. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings.
NCT00119756 ↗ A Safety and Tolerability Study of Paliperidone Palmitate Injected in the Shoulder or the Buttock Muscle in Patients With Schizophrenia Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 2005-06-01 The purpose of this study is to evaluate the safety and tolerability of intramuscular injections (to the buttocks or to the shoulders) of paliperidone palmitate in patients with schizophrenia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Paliperidone Palmitate

Condition Name

Condition Name for Paliperidone Palmitate
Intervention Trials
Schizophrenia 51
Psychotic Disorders 2
Bipolar Disorder 2
Schizoaffective Disorder 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Paliperidone Palmitate
Intervention Trials
Schizophrenia 55
Psychotic Disorders 5
Recurrence 4
Disease 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Paliperidone Palmitate

Trials by Country

Trials by Country for Paliperidone Palmitate
Location Trials
United States 250
Korea, Republic of 17
Spain 13
Germany 12
Ukraine 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Paliperidone Palmitate
Location Trials
California 20
Texas 17
Illinois 14
Florida 14
Ohio 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Paliperidone Palmitate

Clinical Trial Phase

Clinical Trial Phase for Paliperidone Palmitate
Clinical Trial Phase Trials
Phase 4 15
Phase 3 25
Phase 2/Phase 3 1
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Paliperidone Palmitate
Clinical Trial Phase Trials
Completed 49
Recruiting 3
Active, not recruiting 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Paliperidone Palmitate

Sponsor Name

Sponsor Name for Paliperidone Palmitate
Sponsor Trials
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 11
Janssen Scientific Affairs, LLC 6
Janssen Research & Development, LLC 6
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Paliperidone Palmitate
Sponsor Trials
Industry 52
Other 21
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Colorcon
McKesson
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.